Isolated duodenal myeloid sarcoma associated with the CBFβ/MYH11 fusion gene followed by acute myeloid leukemia progression: A case report and literature review

Huang,Bo; You,Peng; Zhu,Ping; Du,Zunguo; Wu,Beiqian; Xu,Xiaoping; Chen,Zi

doi:10.3892/ol.2014.2313

Isolated duodenal myeloid sarcoma associated with the CBFβ/MYH11 fusion gene followed by acute myeloid leukemia progression: A case report and literature review

Authors:
- Bo Huang
- Peng You
- Ping Zhu
- Zunguo Du
- Beiqian Wu
- Xiaoping Xu
- Zi Chen
View Affiliations

Affiliations: Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Gastroenterology, People's Hospital, Peking University, Beijing 100044, P.R. China, Department of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: July 4, 2014 https://doi.org/10.3892/ol.2014.2313
Pages: 1261-1264

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myeloid sarcoma (MS) is a rare disease that presents as an extramedullary tumorous mass of immature myeloid precursors. The majority of MS are identified in acute myeloid leukemia (AML) patients and rarely present as a primary isolated MS without AML. In addition, inversion of chromosome 16 [inv(16)] and the CBFβ/MYH11 fusion gene are rarely associated with MS. The current study reports a female patient with an isolated duodenal MS, who developed AML‑M4 associated with the CBFβ/MYH11 fusion gene and 48,XX,inv(16),+13,+22. A review of previously reported cases of isolated MS with the CBFβ/MYH11 fusion gene was also performed. Isolated MS with the CBFβ/MYH11 fusion gene was often observed in abdominal lesions, with the intestinal tract being the predominantly involved site. In addition, patients with isolated MS with the CBFβ/MYH11 fusion exhibited a high risk of developing systemic AML. The diagnosis of isolated MS may be particularly challenging and, therefore, determining the optimal standard treatment for isolated MS is required.

View Figures

View References

1	Burns A: Observation of Surgical Anatomy, Head and Neck. Thomas Royce and Co; Edinburg: pp. 364–366. 1811
2	Rappaport H: Tumours of the hematopoietic system. Atlas of Tumour Pathology, Section III, Fascicle 8. Armed Force Institute of Pathology; Washington, DC: pp. 241–243. 1996
3	Pileri SA, Orayi A and Falini B: Myeloid sarcoma. WHO Classification of Tumours of Haematopoietic Lymphoid Tissues. Swerdlow S, Campo E, Harris NL, et al: IARC Press; Lyon: pp. 140–141. 2008
4	Xavier SG, Fagundes EM, Hassan R, Bacchi C, Conchon M, Tabak DG, Spector N and Zalcberg IR: Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res. 27:1063–1066. 2003.
5	Zaenker S, Schweyer S, Hasenkamp J, Truemper L and Wulf G: Granulocytic sarcoma by AML M4eo (inv16) after allogeneic stem cell transplantation without bone marrow involvement. Case Rep Hematol. 2011:6929822011.
6	Russell SJ, Giles FJ, Thompson DS, Scanlon DJ, Walker H and Richards JD: Granulocytic sarcoma of the small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16). Cancer Genet Cytogenet. 35:231–235. 1988.
7	Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM and Rowley JD: Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med. 309:630–636. 1983.
8	Billio A, Pianezze G, Amato B and Fabris P: ‘Isolated’ peritoneal granulocytic sarcoma with molecular and chromosomal bone marrow involvement. Haematologica. 87:EIM012002.
9	Morel F, Herry A, Le Bris MJ, Le Calvez G, Marion V, Berthou C and De Braekeleer M: Isolated granulocytic sarcoma followed by acute myelogenous leukemia type FAB-M2 associated with inversion 16 and trisomies 9 and 22. Leukemia. 16:2458–2459. 2002.
10	Quitt M, Elmalach I, Dar H and Aghai E: Isolated chloroma of breast preceding acute nonlymphatic leukemia. Leukemia. 11:1995–1996. 1997.
11	McKenna M, Arnold C, Catherwood MA, Humphreys MW, Cuthbert RJ, Bueso-Ramos C and McManus DT: Myeloid sarcoma of the small bowel associated with a CBFbeta/MYH11 fusion and inv(16)(p13q22): a case report. J Clin Pathol. 62:757–759. 2009.
12	Göhring G, Erlacher M, van Buiren M, Jüttner E, Niemeyer CM and Schlegelberger B: Mesenteric chloroma with t(16;16) followed by acute myelomonocytic leukemia with clonal evolution. Cancer Genet Cytogenet. 179:162–164. 2007.
13	Alvarez P, Navascués CA, Ordieres C, Pipa M, Vega IF, Granero P, Alvarez JA and Rodríguez M: Granulocytic sarcoma of the small bowel, greater omentum and peritoneum associated with a CBFβ/MYH11 fusion and inv(16) (p13q22): a case report. Int Arch Med. 4:32011.
14	Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE and Bennett JM: Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 48:1426–1437. 1981.
15	Breccia M, Mandelli F, Petti MC, D’Andrea M, Pescarmona E, Pileri SA, Carmosino I, Russo E, De Fabritiis P and Alimena G: Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res. 28:1165–1169. 2004.
16	Bakst RL, Tallman MS, Douer D and Yahalom J: How I treat extramedullary acute myeloid leukemia. Blood. 118:3785–3793. 2011.
17	Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, Barnard DR, Wells RJ, Buckley JD, Lange BJ and Woods WG: Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol. 25:760–768. 2003.
18	Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O’Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ and Estey E: Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 113:1370–1378. 2008.
19	Arber DA, Burnning RD, Le Beau MM, et al: Acute myloid leukemia with recurrent genetic abnormalities. WHO Classification of Tumours of Haematopoietic Lymphoid Tissues. Swerdlow S, Campo E, Harris NL, et al: IARC Press; Lyon: pp. 110–123. 2008
20	Byrd JC, Edenfield WJ, Shields DJ and Dawson NA: Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol. 13:1800–1816. 1995.
21	Tóth E, Balint I, Deák B and Orosz Z: Complex pathological diagnosis of granulocytic sarcoma: apropos of a case. Pathol Res Pract. 198:55–57. 2002.
22	Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, Djunic I, Mitrovic M and Tomin D: Is there a ‘gold’ standard treatment for patients with isolated myeloid sarcoma? Biomed Pharmacother. 67:72–77. 2013.
23	Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, et al; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l’Enfant; Acute Leukemia French Association and Bordeaux-Grenoble-Marseille-Toulouse cooperative groups. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 102:462–469. 2003.
24	Dombret H, Preudhomme C and Boissel N: Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol. 16:92–97. 2009.